What is LivaNova's SG&A?

LivaNova (LIVN) reported SG&A of $143.57M in Q1 2026.

How has LivaNova's SG&A changed year-over-year?

LivaNova's SG&A increased by 11.2% year-over-year, from $129.15M to $143.57M.

What is the long-term trend for LivaNova's SG&A?

Over 4 years (2021 to 2025), LivaNova's SG&A has grown at a 3.8% compound annual growth rate (CAGR), from $471.9M to $548.81M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

LivaNova LIVN SG&A

SG&A at other companies

AbbottABT

$3.74B+22.2%

HaemoneticsHAE

$120.93M+5.0%

MedtronicMDT

$3.06B+12.4%

ITG

Integer HoldingsITGR

$58.71M+14.8%

Boston ScientificBSX

$1.78B+11.5%

StrykerSYK

$2.28B-0.8%

Segments

By segment

See full

Cardiopulmonary$59.85M+2.3%

Neuromodulation$52.62M+10.6%

Other financials

Income statement

See full

Revenue$362.3M+14.3%

Gross profit$243.7M+12.7%

Operating income$41.5M-14.7%

Net income$22.3M+107%

EPS (diluted)$0.40+107%

Balance sheet

See full

Cash & equivalents$539.7M-26.9%

Total debt$340.9M-49.7%

Total equity$1.2B+17.1%

Total assets$2.5B-1.7%

Cash flow

See full

Operating cash flow$15.2M-36.5%

CapEx$14.3M+32.4%

Free cash flow$926.0K-93.0%

Valuation

See full

Market cap$4.32B+62.8%

Profitability

See full

Gross margin67.5%-0.5pp

Operating margin13.4%+0.8pp

Net margin-16.1%-18.0pp

FCF margin11.2%-0.2pp

Returns & leverage

See full

Return on equity-17.6%-19.5pp

Debt / equity0.3×-0.4×

Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is LivaNova's SG&A?: LivaNova (LIVN) reported SG&A of $143.57M in Q1 2026.
How has LivaNova's SG&A changed year-over-year?: LivaNova's SG&A increased by 11.2% year-over-year, from $129.15M to $143.57M.
What is the long-term trend for LivaNova's SG&A?: Over 4 years (2021 to 2025), LivaNova's SG&A has grown at a 3.8% compound annual growth rate (CAGR), from $471.9M to $548.81M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.